Narinder Pal Bhalla

CIK: 0002109299

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LXEO

Lexeo Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

LXEO
Lexeo Therapeutics, Inc.
Sep 24, 2026
Award(A)
Stock Option (right to buy)
Direct
54.8K shares-
LXEO
Lexeo Therapeutics, Inc.
Sep 14, 2026
Award(A)
Direct
2.7K shares at avg. $3.58$10K
LXEO
Lexeo Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
22.3K shares at avg. $4.42$99K
LXEO
Lexeo Therapeutics, Inc.
Jun 29, 2026
Award(A)
Direct
55K shares-
LXEO
Lexeo Therapeutics, Inc.
Feb 13, 2026
Award(A)
Direct
49.5K shares-

		Type	Shares	Price		Ownership
Sep 24, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A) Stock Option (right to buy)	54,750	-	-	Direct
Sep 14, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A)	2,714	$3.58	$9,713	Direct
Jul 1, 2026	LXEO Lexeo Therapeutics, Inc.	Sale(S)	22,306	$4.42	$98,593	Direct
Jun 29, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A)	55,000	-	$0	Direct
Feb 13, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A)	49,500	-	$0	Direct

1-5 of 5 transactions

About Bhalla Narinder Pal

Bhalla Narinder Pal (SEC CIK 0002109299) files insider reports with the SEC as Chief Medical Officer of Lexeo Therapeutics, Inc. (LXEO).

Signal8 holds 4 ownership filings by Bhalla Narinder Pal (1 Form 3, 3 Form 4), filed between Feb 5, 2026 and Sep 28, 2026. Those filings report 5 transactions, from Feb 13, 2026 to Sep 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bhalla Narinder Pal's filings is in NEW YORK, NY.

Recent filings by Bhalla Narinder Pal

Sep 24, 2026: Grant or award of LXEO derivative securities (Form 4, code A).
Sep 14, 2026: Grant or award of LXEO shares (Form 4, code A).
Jul 1, 2026: Open-market sale of LXEO shares (Form 4, code S).
Jun 29, 2026: Grant or award of LXEO shares (Form 4, code A).
Feb 13, 2026: Grant or award of LXEO shares (Form 4, code A).

Other insiders filing for Lexeo Therapeutics, Inc. (LXEO)

Tamayo Louis Edward, Chief Financial Officer
Otero Jose Manuel, Chief Operating Officer
Townsend Richard Nolan, Chief Executive Officer
Altschuler Steven, Director
Agger Mette Kirstine, Director
COOPERSTONE BRENDA, Director

How to read Form 4 transaction codes